子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 通过4轮连续PCR或阻断PCR或其全基因合成的方法进行的含有基因特异的条形码的粟酒裂殖酵母杂合缺失突变体的全基因组构建 | CN200880128751.4 | 2008-08-27 | CN102016022B | 2014-05-14 | 许光来; 金东旭; 元美善; 俞香淑; 金东燮; 朴翰浯; 郑璟淑; 张荣珠; 南美英; 韩尚助; 崔信正; 白昇泰; 金炯培; 许京善; 李惠美; 李慜镐; 朴助英 |
| 提供用于制备基因靶向的杂合缺失粟酒裂殖酵母的方法，包括用缺失盒转化粟酒裂殖酵母，该缺失盒由4轮连续PCR、阻断PCR或全基因合成构建，含有同源重组位点。还提供了由该方法制备的基因靶向的杂合缺失粟酒裂殖酵母突变体，和基因靶向的杂合缺失粟酒裂殖酵母突变体文库。此外，该文库在构建用于筛选药物作用方式的方法和试剂盒中有用。 | ||||||
| 2 | 通过4轮连续PCR或阻断PCR或其全基因合成的方法进行的含有基因特异的条形码的粟酒裂殖酵母杂合缺失突变体的全基因组构建 | CN200880128751.4 | 2008-08-27 | CN102016022A | 2011-04-13 | 许光来; 金东旭; 元美善; 俞香淑; 金东燮; 朴翰浯; 郑璟淑; 张荣珠; 南美英; 韩尚助; 崔信正; 白昇泰; 金炯培; 许京善; 李惠美; 李慜镐; 朴助英 |
| 提供用于制备基因靶向的杂合缺失粟酒裂殖酵母的方法，包括用缺失盒转化粟酒裂殖酵母，该缺失盒由4轮连续PCR、阻断PCR或全基因合成构建，含有同源重组位点。还提供了由该方法制备的基因靶向的杂合缺失粟酒裂殖酵母突变体，和基因靶向的杂合缺失粟酒裂殖酵母突变体文库。此外，该文库在构建用于筛选药物作用方式的方法和试剂盒中有用。 | ||||||
| 3 | 一种DNA编码分子库及化合物筛选方法 | CN201610871861.6 | 2016-09-30 | CN107130299A | 2017-09-05 | 李笑宇 |
| 本发明公开了一种DNA编码分子库及化合物筛选方法。一种DNA编码分子库，其引入一具有8～12个碱基的短链DNA，所述短链DNA一端具有光交联基团。使用本发明的DNA编码分子库的筛选方法，使得蛋白质靶点不需纯化和固载，并且能够直接应用于膜蛋白、蛋白质复合体、活细胞、病理组织等其它方法无法应用的药物靶点。 | ||||||
| 4 | 用于确定基因组完整性和/或通过确定性限制位点全基因组扩增获得的DNA序列的文库质量的方法和试剂盒 | CN201480074845.3 | 2014-12-04 | CN106030307A | 2016-10-12 | 克里斯托夫·安德烈亚斯·克莱因; 伯恩哈德·米夏埃尔·波尔策; 尼科洛·马纳雷西 |
| 本发明涉及用于确定样品基因组的完整性和/或由样品的基因组的确定性限制位点全基因组扩增(DRS‑WGA)获得的DNA序列的文库的质量的方法，包括以下步骤：(a)提供DNA序列的文库：(b)使用至少一个第一引物对、一个第二引物对和一个第三引物对通过PCR扩增DNA序列的文库，引物对各自杂交至具有1000bp至5000bp长度并对应分别位于第一、第二和第三染色体臂上的基因组的序列的文库的DNA序列，扩增的步骤产生各自为50bp至1000bp并各自具有与其他不同的尺寸的第一、第二和第三PCR产物；(c)检测第一、第二和第三PCR产物；(d)将第一、第二和第三PCR产物的存在与样品的基因组的完整性和/或DNA序列的文库的质量相关联。 | ||||||
| 5 | 带标签DNA片段的产生 | CN201480072947.1 | 2014-12-11 | CN105899683A | 2016-08-24 | 约安娜·安德里欧; 方南; 德科·洛斐尔特; 安尼卡·彼得罗夫斯基 |
| 本发明涉及用于产生靶DNA的带标签DNA片段和与其相关的核酸分子的新方法、试剂盒和用途。 | ||||||
| 6 | 4 stage continuous pcr, 4 stage block pcr or production method of gene targeting heterozygous fission yeast strain containing a strain-specific bar code using a gene synthesis method, | JP2011506175 | 2008-08-27 | JP5608637B2 | 2014-10-15 | リー ホー、クワン; ウク キム、ドン; スン ウォン、ミ; スク ユ、ヒャン; サップ キム、ドン; オウ パク、ハン; スク チュン、キュン; ジュ チャン、ヨン; ヨン ナム、ミ; ジョ ハン、サン; ジュン チェ、シン; テ ベク、スン; バイ キム、ヒョン; スン ホ、キュン; ミ リー、ヘ; ホ リー、ミン; ヨン パク、ジョ |
| 7 | Polymorphisms to predict the platinum coordination complexes induced ototoxicity | JP2009536572 | 2007-11-15 | JP2010508859A | 2010-03-25 | カールトン、ブルース; ハイデン、マイケル; ロス、コリン |
| Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of ototoxicity in response to receiving one or more platinum-coordinating compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of ototoxicity. | ||||||
| 8 | 4 stage continuous pcr, 4 stage block pcr or production method of gene targeting heterozygous fission yeast strain containing a strain-specific bar code using a gene synthesis method, | JP2011506175 | 2008-08-27 | JP2011517957A | 2011-06-23 | スン ウォン、ミ; ウク キム、ドン; サップ キム、ドン; バイ キム、ヒョン; ジュン チェ、シン; ジュ チャン、ヨン; スク チュン、キュン; ヨン ナム、ミ; ヨン パク、ジョ; オウ パク、ハン; ジョ ハン、サン; テ ベク、スン; スン ホ、キュン; リー ホー、クワン; スク ユ、ヒャン; ミ リー、ヘ; ホ リー、ミン |
| 本発明は、相同組換えに使用される欠損カセットを４段階連続的ＰＣＲ、４段階ブロックＰＣＲ、または遺伝子合成方法を用いて効率よく製造し、これを用いて分裂酵母（Ｓｃｈｉｚｏｓａｃｃｈａｒｏｍｙｃｅｓ ｐｏｍｂｅ）を形質転換して、遺伝子標的化分裂酵母菌株を製造する方法に関する。 また本発明は、前記方法によって製造された遺伝子標的化分裂酵母ヘテロ接合菌株および遺伝子標的化分裂酵母ヘテロ接合菌株ライブラリーに関する。 また本発明は、前記ライブラリーを用いた薬物作用点の探索方法および前記ライブラリーを含む薬物スクリーニングキットに関する。
【選択図】図７ |
||||||
| 9 | Polymorphisms to predict the anthracycline-induced cardiotoxicity | JP2009536571 | 2007-11-15 | JP2010508858A | 2010-03-25 | カールトン、ブルース; ハイデン、マイケル; ロス、コリン |
| Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of cardiotoxicity in response to receiving one or more anthracycline compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of cardiotoxicity. | ||||||
| 10 | Specific to the labeled solid support | JP50641597 | 1996-07-17 | JPH11509542A | 1999-08-24 | エデン シュウテ，リチャード; ジェフリー メイン，ブライアン |
| (57)【要約】 化合物ライブラリの単一メンバーが会合する固体支持体を各々が含む複数の異なるユニットを含む化合物ライブラリであって、各固体支持体が化合物ライブラリの会合メンバーの合成において第一の選択反応を同定しうる固有ラベルとして働く定義された化学組成を有する、化合物ライブラリ。 | ||||||
| 11 | Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification | EP13195770.6 | 2013-12-04 | EP2881739A1 | 2015-06-10 | Klein, Christoph Andreas; Polzer, Bernhard Michael; Manaresi, Nicolò |
The present invention relates to a method for determining the integrity of the genome of a sample and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample comprising the steps of: (a) providing the library of DNA sequences; (b) amplifying the library of DNA sequences by PCR using at least one first primer pair which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp and corresponding to a sequence of the genome located on a first chromosome arm, the step of amplifying giving rise to a first PCR product from 50 to 1000 bp; (c) detecting the first PCR product; (d) correlating the presence of the first PCR product with the integrity of the genome and/or the quality of the library of DNA sequences. The present invention further relates to a related kit and uses thereof.
|
||||||
| 12 | Polymorphisms predictive of anthracycline-induced cardiotoxicity | EP11150040.1 | 2007-11-15 | EP2312024A1 | 2011-04-20 | Hayden, Michael; Carleton, Bruce; Ross, Colin |
Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of cardiotoxicity in response to receiving one or more anthracycline compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of cardiotoxicity. |
||||||
| 13 | POLYMORPHISMS PREDICTIVE OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY | EP07845535 | 2007-11-15 | EP2102392A4 | 2010-07-14 | HAYDEN MICHAEL; CARLETON BRUCE; ROSS COLIN |
| 14 | POLYMORPHISMS PREDICTIVE OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY | EP07845535.9 | 2007-11-15 | EP2102392A1 | 2009-09-23 | HAYDEN, Michael; CARLETON, Bruce; ROSS, Colin |
| Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of cardiotoxicity in response to receiving one or more anthracycline compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of cardiotoxicity. | ||||||
| 15 | METHOD AND KIT FOR DETERMINING THE GENOME INTEGRITY AND/OR THE QUALITY OF A LIBRARY OF DNA SEQUENCES OBTAINED BY DETERMINISTIC RESTRICTION SITE WHOLE GENOME AMPLIFICATION | US15101299 | 2014-12-04 | US20180187254A1 | 2018-07-05 | Christoph Andreas Klein; Bernhard Michael POLZER; Nicolò MANARESI |
| A method for determining the integrity of the genome of a sample and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification can include (a) amplifying the library of DNA sequences to produce first, second, and third PCR products each of a different size from 50 bp to 1000 bp, by PCR using at least one first primer pair, one second primer pair and one third primer pair, the primer pairs each hybridizing to a DNA sequence of the library having a length from 1000 bp to 5000 bp and corresponding to a sequence of the genome located respectively on a first, second and third chromosome arm; (b) detecting the first, second and third PCR products; (c) correlating the presence of the first, second and third PCR products with the integrity of the genome of the sample and/or the quality of the library. | ||||||
| 16 | System and Methods for Detecting Genetic Variation | US14512369 | 2014-10-10 | US20150205914A1 | 2015-07-23 | Hunter RICHARDS; Eric EVANS; Balaji SRINIVASAN; Subramaniam SRINIVASAN; Abhik SHAH; A. Scott PATTERSON; Clement CHU |
| The invention provides methods, apparatuses, and compositions for high-throughput amplification sequencing of specific target sequences in one or more samples. In some aspects, barcode-tagged polynucleotides are sequenced simultaneously and sample sources are identified on the basis of barcode sequences. In some aspects, sequencing data are used to determine one or more genotypes at one or more loci comprising a causal genetic variant. In some aspects, systems and methods of detecting genetic variation are provided. | ||||||
| 17 | REIMMUNIZATION AND ANTIBODY DESIGN | US14493488 | 2014-09-23 | US20150098936A1 | 2015-04-09 | Janus Beierholm Larsen |
| The present invention relates to methods for harvesting of antibodies from an antibody library. The antibodies are harvested by utilising a certain epitope that is analogous to the epitope of the antigen used for immunization but that may differ in global physical and biochemical properties allowing the production of antibodies against antigens that normally cannot be utilised as immunizing agents. The present invention furthermore relate to fields of use for harvested antigens in industry, agriculture and healthcare. | ||||||
| 18 | TERPENE-BASED COMPOSITIONS, PROCESSES, METHODOLOGIES FOR CREATION AND PRODUCTS THEREBY | US14467565 | 2014-08-25 | US20150080265A1 | 2015-03-19 | Sytze Elzinga; Jeffrey C. Raber |
| Compositions which are fragrant and contain at least a member set culled from a library of compositions, each being comprised of sub-combinations of selected terpenes. Fragrances that mimic that of various states of organic and synthetic aromatics including products, processes and those from non-combusted plant products, among other things, uniquitous products, processes, medicinals, and related moieties leverage databases of all known terpene groupings are offered for consideration, and have been provided, according to the instant teachings. | ||||||
| 19 | DNA Methylation Changes Associated with Major Psychosis | US13958204 | 2013-08-02 | US20140038840A1 | 2014-02-06 | Arturas PETRONIS; Jonathan MILL; James FLANAGAN; Sun-Chong WANG |
| The present invention provides a method of identifying one or more epigenetic markers associated with psychosis-associated diseases such as bipolar disease or schizophrenia, the method comprising a) obtaining a first group of samples comprising genomic DNA from a plurality of bipolar or schizophrenic subjects and a second group of samples comprising genomic DNA from a plurality of control subjects; b) performing DNA methylation analysis to determine methylation differences in one or more DNA regions between the first group and second group of samples, wherein a methylation difference in a DNA region is indicative of an epigenetic marker associated with bipolar disease or schizophrenia. The invention also provides one or more epigenetic markers associated with psychosis-associated diseases such as bipolar disease or schizophrenia. | ||||||
| 20 | POLYMORPHISMS PREDICTIVE OF PLATINUM-COORDINATING COMPLEX INDUCED OTOTOXICITY | US14035763 | 2013-09-24 | US20140023726A1 | 2014-01-23 | Michael Hayden; Bruce Carleton; Colin Ross |
| Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of ototoxicity in response to receiving one or more platinum-coordinating compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of ototoxicity. | ||||||
QQ群二维码
意见反馈
意见反馈